Implementation of 3D-printed pharmaceuticals in geriatric/neurological care concepts: opportunities, barriers and perspectives

Implementation of 3D-printed pharmaceuticals in geriatric/neurological care concepts: opportunities, barriers and perspectives - GeriPrint

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040007

Enrollment

480

Registered

2026-04-23

Start date

2026-04-29

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R13 G20 G21

Interventions

Group 1: Observational study: Questionnaire taken after taking the 3D-printed tablet compared to a standard tablet Repeated intake/one-time questionnaire survey

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: patients with prescription for amlodipine 5 mg or ramipril 5 mg or spironolactone 12,5 mg or spironolactone 25 mg; hospitalized patients

Exclusion criteria

Exclusion criteria: Age < 50 years

Design outcomes

Primary

Measure	Time frame
Reaching the planned number of 450-480 patients Investigation of the acceptance of a new galenic dosage form (3D-printed tablet) in a geriatric/neurological patient cohort	—

Countries

Germany

Contacts

Public ContactJana Giesel-Gerstmeier

Helios Kliniken GmbH

jana.giesel-gerstmeier@helios-gesundheit.de+4915201885294

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026